These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7865167)

  • 1. Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats.
    Kretschmer BD; Winterscheid B; Danysz W; Schmidt WJ
    J Neural Transm Gen Sect; 1994; 95(2):123-36. PubMed ID: 7865167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
    Verma A; Kulkarni SK
    Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
    Papa SM; Engber TM; Boldry RC; Chase TN
    Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
    Moore NA; Blackman A; Awere S; Leander JD
    Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata.
    Ozer H; Ekinci AC; Starr MS
    Brain Res; 1997 Nov; 777(1-2):51-9. PubMed ID: 9449412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens.
    Kretschmer BD; Schmidt WJ
    J Neurosci; 1996 Feb; 16(4):1561-9. PubMed ID: 8778305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.
    Hauber W; Neuscheler P; Nagel J; Müller CE
    Eur J Neurosci; 2001 Oct; 14(8):1287-93. PubMed ID: 11703457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7- dichloro-kynurenic acid, glycine site antagonists.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Pol J Pharmacol; 1994; 46(3):115-24. PubMed ID: 8000442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
    Boulay D; Depoortere R; Oblin A; Sanger DJ; Schoemaker H; Perrault G
    Eur J Pharmacol; 2000 Mar; 391(1-2):63-73. PubMed ID: 10720636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration.
    Ushijima I; Mizuki Y; Suetsugi M; Akimoto T; Yamada M
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):709-21. PubMed ID: 9682282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
    Banasikowski TJ; Beninger RJ
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1525-34. PubMed ID: 22093169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
    Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
    Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
    Kostrzewa RM; Kastin AJ
    Brain Res Bull; 1993; 31(6):707-12. PubMed ID: 8100182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-D-aspartate receptors.
    Hauber W
    Neuroscience; 1996 Jul; 73(1):121-30. PubMed ID: 8783236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse.
    Starr MS; Starr BS
    Eur J Pharmacol; 1993 Dec; 250(2):239-46. PubMed ID: 7906652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.
    Kretschmer BD
    Neurosci Lett; 1994 Sep; 179(1-2):115-8. PubMed ID: 7845605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental plasticity in the D1- and D2-mediation of motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM; Ughrin Y; Bruno JP
    Dev Psychobiol; 1996 Dec; 29(8):653-66. PubMed ID: 8958479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system.
    Striem S; Bar-Joseph A; Berkovitch Y; Biegon A
    Eur J Pharmacol; 1997 Nov; 338(3):205-13. PubMed ID: 9424014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats.
    Kretschmer BD; Bubser M; Schmidt WJ
    Eur J Pharmacol; 1995 Jun; 280(1):37-45. PubMed ID: 7498252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole, a glutamate release inhibitor, and motor behavior.
    Kretschmer BD; Kratzer U; Schmidt WJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):181-90. PubMed ID: 9750003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.